Sortilin‐related receptor is a druggable therapeutic target in breast cancer

In breast cancer, the currently approved anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) therapies do not fully meet the expected clinical goals due to therapy resistance. Identifying alternative HER2‐related therapeutic targets could offer a means to overcome these resistance mechanisms. We hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Al‐Akhrass, Hussein, Pietilä, Mika, Lilja, Johanna, Vesilahti, Ella‐Maria, Anttila, Johanna M., Haikala, Heidi M., Munne, Pauliina M., Klefström, Juha, Peuhu, Emilia, Ivaska, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732349/
https://www.ncbi.nlm.nih.gov/pubmed/34564954
http://dx.doi.org/10.1002/1878-0261.13106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732349/
https://www.ncbi.nlm.nih.gov/pubmed/34564954
http://dx.doi.org/10.1002/1878-0261.13106

Ejemplares similares